Becton, Dickinson and Company (NYSE:BDX) to Issue $1.05 Quarterly Dividend

Becton, Dickinson and Company (NYSE:BDX) announced a quarterly dividend on Tuesday, April 28th. Shareholders of record on Tuesday, June 9th will be given a dividend of 1.05 per share by the medical instruments supplier on Tuesday, June 30th. This represents a c) dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, June 9th.

Becton, Dickinson and Company has raised its dividend by an average of 0.1%annually over the last three years and has raised its dividend every year for the last 53 years. Becton, Dickinson and Company has a payout ratio of 28.5% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Becton, Dickinson and Company to earn $13.73 per share next year, which means the company should continue to be able to cover its $4.20 annual dividend with an expected future payout ratio of 30.6%.

Becton, Dickinson and Company Trading Down 1.9%

Shares of BDX stock opened at $146.75 on Wednesday. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67. The stock has a market cap of $41.79 billion, a price-to-earnings ratio of 23.95, a PEG ratio of 10.68 and a beta of 0.29. The stock has a 50-day moving average of $162.11 and a 200-day moving average of $182.48.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company had revenue of $4.49 billion for the quarter, compared to analyst estimates of $5.15 billion. During the same period in the previous year, the firm earned $3.43 earnings per share. The firm’s quarterly revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities research analysts forecast that Becton, Dickinson and Company will post 12.56 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on BDX. Piper Sandler reduced their price objective on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Zacks Research raised shares of Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. JPMorgan Chase & Co. dropped their target price on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a report on Tuesday, February 10th. Citigroup cut their price target on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Finally, Barclays began coverage on Becton, Dickinson and Company in a research report on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 price objective for the company. Six equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $189.08.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.